All News

Public health expert Kelly Moore, MD, MPH, president and CEO of immunize.org, says the news is good for now, but the uninsured could be at future risk.

Measles vaccine coverage must reach 93% to maintain herd immunity but in 1 postelimination outbreak, the level reached only 80% in school-aged children.

The FDA has approved guselkumab for children aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis, making it the first IL-23 inhibitor authorized for pediatric use.

Your daily dose of the clinical news you may have missed.

The annual meeting of the American Academy of Family Physicians is a unique chance to choose continuing education on just about any topic a family physician could imagine.

Review FDA-approved drugs that may soon find a place in your prescribing routine, including new treatments for UTIs, acute pain, migraine, diabetes, and more.

Public health officials across states and regions are "thinking on their feet" about how best to protect public health given the upheavel in federal vaccine policy, Moore said.

The European Commission granted marketing authorization for the Lilly mAb based on data from the phase 3 TRAILBLAZER-ALZ 2 and 6 clinical trials.

Novo Nordisk aims to revolutionize diabetes care with its resubmission for insulin icodec, a potential first once-weekly basal insulin for type 2 diabetes therapy in adults.

Your daily dose of the clinical news you may have missed.

Adult vaccine-preventable diseases cost $26.5B annually in the US. See key gaps, barriers, and strategies primary care physicians can use to boost immunization.

"The foundation of science in the new iteration of the ACIP is uncertain at best," William Schaffner, MD, observed. He is concerned about where that might lead.

William Grady, MD, highlights the convenience and compliance of blood-based tests compared to colonoscopy and stool-based tests for colorectal cancer screening.

Moore, a past voting member of the ACIP, is unsure how the CDC will respond to adding "speculative concerns" to a piece of information given to every person who recieves a vaccine.

The approval is based on phase 3 trials showing durable IGF-1 control, symptom relief, and a favorable safety profile among adults with acromegaly.

Your daily dose of the clinical news you may have missed.

William Grady, MD, talks about the latest research in colorectal cancer, including treatments targeting senescent cells that contribute to tumor formation.

Moore, president and CEO of immunize.org, has deep roots in public health and advocacy, vaccine program implementation, and immunization education.